# A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis

> **NCT00295282** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 24 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** MDX-1100 (anti-CXCL10 human monoclonal antibody)

## Key facts

- **NCT ID:** NCT00295282
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2010-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295282, "A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00295282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*